ACCESSWIRE
04 Aug 2022, 20:01 GMT+10
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets
VANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ('RepliCel' or the 'Company'), a company developing novel, next-generation injection technologies as well as cell-based regenerative medicine products in aesthetics and orthopedics, is pleased to announce the granting of several patents covering novel aspects of the DermaPrecise™ product portfolio, as well as the granting and/or allowance of four other patent applications for its skin rejuvenation and tendon regeneration technologies.
RepliCel has now been granted patents for DermaPrecise™ by the patent offices in the Unites States (Patent No. 11,311,684) and Japan (Patent No. 6718472B2), both of which are key, near-term markets for RepliCel's cell therapies and the DermaPrecise™ product line. RepliCel has also received a notice of allowance in New Zealand for a corresponding patent application.
'RepliCel has a growing number of allowed and granted patents globally with respect to its innovative DermaPrecise™ injector, control unit and consumables,' stated RepliCel President and CEO, R. Lee Buckler. 'With the positive results we are now seeing in testing of the DermaPrecise™ injection system, we continue to generate patentable innovations which serve to strengthen the clinical and commercial value of this next-generation injection technology.'
Additionally, RepliCel has been granted:
About the DermaPrecise Product Line
The DermaPrecise™ Injector is an electronic injection system designed to offer new levels of control over any injection into the intro-dermal and subcutaneous layers for which precision of depth, dose and/or delivery matters.
About RepliCel's Skin and Tendon Programs
Both RepliCel's cell-based skin rejuvenation product (RCS-01) and its cell-based tendon regeneration product (RCT-01) have been the subject of successful phase 1 clinical studies. RepliCel is currently preparing for next-phased clinical testing and commercialization of two cell-based regenerative medicines in Japan. In China, RepliCel's partner, YOFOTO China Health Company, is currently preparing for phase 2 studies in China of these same therapies in collaboration with RepliCel.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function. These cell therapy product candidates are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles.
The Company's cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 has been the subject of successful safety and dose-finding clinical studies and is now the subject of its third clinical study evaluating efficacy for the treatment of male and female hair loss due to androgenetic alopecia. This ongoing study is being funded by Shiseido Company Limited pursuant to a license agreement which has now been terminated but is the subject of an arbitration regarding Shiseido's rights to the product for Asia. RepliCel maintains the undisputed rights to RCH-01 for the rest of the world. RCT-01 and RCS-01 are exclusively licensed in Greater China to YOFOTO (China) Health Company. RepliCel and YOFOTO are currently co-developing these products in China. RepliCel maintains the rights to these products outside of Greater China.
RepliCel has also developed a proprietary injection device (DermaPrecise™) and related consumables, which is expected to improve the administration of its cell therapy products and certain other injectables. YOFOTO has exclusively licensed the commercial rights for the DermaPrecise™ device and consumables in Greater China for dermatology applications and is expected to first launch the product in Hong Kong upon it being approved for market launch in either the United States or Europe. Please visit replicel.com for additional information.
Notable Facts:
For more information, please contact:
Lee Buckler, CEO and President
604-248-8693
[email protected]
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: RepliCel Life Sciences Inc.
Get a daily dose of Raleigh Times news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Raleigh Times.
More InformationBURBANK, California: A note by Needham media analyst Laura Martin released this week revealed that CEO Bob Iger told investors ...
TOKYO, Japan: This week, Toshiba revealed that a tender offer worth US$14 billion from Japan Industrial Partners (JIP) was a ...
HANOI, Vietnam: While the European Union (EU) is set to impose tariffs on its Chinese rivals, Vietnamese electric vehicle (EV) ...
BEIJING, China: In a country where weddings are traditionally grand and expensive events, China's wedding industry, estimated at some US$500 ...
PARIS, France: Amid the imminent launch of the iPhone 15, unions representing Apple store workers in France have called for ...
SEATTLE, Washington: To expand its next-day delivery services for shoppers, Amazon said it plans to hire 250,000 more U.S. workers ...
(Photo credit: Chris Pietsch/The Register-Guard / USA TODAY NETWORK) Bo Nix passed for three touchdowns and rushed for one as ...
ANNAPOLIS, Md. - Residents in parts of coastal North Carolina and Virginia experienced flooding Saturday after Tropical Storm Ophelia made ...
(Photo credit: Charles LeClaire-USA TODAY Sports) Drake Maye ran for two touchdowns and threw an unconventional pass for another touchdown ...
(Photo credit: John David Mercer-USA TODAY Sports) FORT WORTH, Texas -- John Hunter Nemechek made the winning pass with seven ...
(Photo credit: David Butler II-USA TODAY Sports) No. 18 Duke's defense dominated and running back Jordan Waters ran for two ...
ANNAPOLIS, Md. - Tropical Storm Ophelia made landfall in North Carolina early Saturday with estimated maximum winds of 110 kilometers ...